The estimated Net Worth of Mark Patrick Guerin is at least $551 Mille dollars as of 13 March 2024. Mr Guerin owns over 8,666 units of Onconova Therapeutics Inc stock worth over $38,567 and over the last 10 years he sold ONTX stock worth over $0. In addition, he makes $512,192 as Chief Financial Officer at Onconova Therapeutics Inc.
Mr has made over 11 trades of the Onconova Therapeutics Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 8,666 units of ONTX stock worth $8,666 on 13 March 2024.
The largest trade he's ever made was buying 87,500 units of Onconova Therapeutics Inc stock on 25 November 2019 worth over $17,500. On average, Mr trades about 6,563 units every 90 days since 2014. As of 13 March 2024 he still owns at least 38,567 units of Onconova Therapeutics Inc stock.
You can see the complete history of Mr Guerin stock trades at the bottom of the page.
Mark Patrick Guerin CPA is the Chief Financial Officer at Onconova Therapeutics Inc.
As the Chief Financial Officer of Onconova Therapeutics Inc, the total compensation of Mr CPA at Onconova Therapeutics Inc is $512,192. There are 2 executives at Onconova Therapeutics Inc getting paid more, with Dr. Steven M. Fruchtman having the highest compensation of $865,438.
Mr CPA is 52, he's been the Chief Financial Officer of Onconova Therapeutics Inc since . There are 9 older and 2 younger executives at Onconova Therapeutics Inc. The oldest executive at Onconova Therapeutics Inc is Henry Bienen, 77, who is the Director.
Mark's mailing address filed with the SEC is C/O ONCONOVA THERAPEUTICS, INC, 12 PENNS TRAIL, NEWTOWN, PA, 18940.
Over the last 12 years, insiders at Onconova Therapeutics Inc have traded over $1,631,795 worth of Onconova Therapeutics Inc stock and bought 27,892,613 units worth $51,994,589 . The most active insiders traders include Capital, Llc Armistice Capi..., Capital Management, Llc 683 e Capital Partners L P Tyndall. On average, Onconova Therapeutics Inc executives and independent directors trade stock every 40 days with the average trade being worth of $294,478. The most recent stock trade was executed by Mark Patrick Guerin on 13 March 2024, trading 8,666 units of ONTX stock currently worth $8,666.
onconova therapeutics, inc. (nasdaq: ontx) is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer. using a proprietary chemistry platform, onconova has created an extensive library of targeted anti-cancer agents designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. onconova has three product candidates in clinical trials and six active pre-clinical programs. onconova seeks to develop products that improve the outcome for cancer patients by directly addressing the disease, its recurrence, and the burden of side-effects associated with current methods of treatment.
Onconova Therapeutics Inc executives and other stock owners filed with the SEC include: